Trial Profile

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy Alone for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NICE 2): a Multi-center, Randomized Phase II Trial

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer; Thoracic neoplasms
Focus Therapeutic Use
Acronyms NICE-2 Study

17 Oct 2024 Protocol has been amended to include changes in study phase, planned patients number and primary outcome.
17 Oct 2024 Planned number of patients changed from 204 to 426.
17 Oct 2024 Planned End Date changed from 6 Mar 2026 to 31 Dec 2030.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com